Quick Answer
Orthovisc denials are common, particularly from commercial plans that prefer lower-cost HA products. Orthovisc occupies a middle ground in the HA market — it is a high-molecular-weight, ultra-pure product administered in 3-4 injections. Appeals succeed when you document why Orthovisc is the right choice for your specific situation. This guide walks you through the process.
Why Orthovisc Injections Get Denied
Orthovisc (high molecular weight hyaluronan) is manufactured by Anika Therapeutics and distributed by DePuy Synthes (Johnson & Johnson). It is known for its high purity and high molecular weight, which some physicians prefer for longer-lasting relief.
1. Medical Necessity Not Established
The insurer concluded that your medical records did not demonstrate that viscosupplementation is medically necessary. This could mean your osteoarthritis severity was not clearly documented, your imaging was outdated, or your functional limitations were not adequately described in the chart notes.
2. Conservative Treatment Failure Not Documented
Plans require evidence of at least 3 months of failed conservative therapy. This means specific records showing physical therapy sessions attended, medications tried with dosages and duration, and the reasons each treatment was insufficient. General statements that you “tried PT and medications” without supporting detail are not accepted.
3. Insurer Prefers a Different HA Product
Some commercial insurers maintain preferred product lists and may deny Orthovisc in favor of a less expensive alternative like Hyalgan or Supartz. In these cases, your appeal needs to explain why Orthovisc is specifically necessary for you, such as prior success with Orthovisc, intolerance of the preferred product, or physician recommendation based on clinical factors.
4. Injection Frequency Limits
Most plans allow one Orthovisc series every 6 months per knee. Claims submitted before the 6-month window has elapsed will be denied. Some plans impose a 12-month restriction.
5. Prior Authorization Not Obtained
Most commercial and Medicare Advantage plans require PA for Orthovisc. Treatment administered without prior approval results in automatic denial.
Product Preference Denials
If your denial letter mentions “preferred alternative available” or “non-formulary product,” the insurer is not denying viscosupplementation itself — they want you to use a different brand. Your appeal strategy should focus on why Orthovisc specifically is needed, or your provider may consider switching to the preferred product if clinically appropriate.
Step-by-Step Appeal Process
Step 1: Review Your Denial Letter
Determine whether the denial is for viscosupplementation in general or for Orthovisc specifically. This distinction changes your appeal strategy. If the denial is product-specific, you need to justify why Orthovisc rather than another HA product. If it is a general medical necessity denial, focus on clinical documentation.
Step 2: Gather Supporting Documentation
- Imaging reports: Recent knee X-rays (within 12 months) showing osteoarthritis with specific findings documented
- Conservative treatment records: Detailed notes with dates, provider names, session counts for PT, medication names and dosages for pharmacotherapy, and outcomes for each treatment
- Functional impact documentation: WOMAC or VAS scores, or provider notes detailing specific limitations in walking distance, stair climbing, sleep, and daily activities
- Orthovisc-specific justification: Prior successful treatment with Orthovisc (dates, duration of relief), adverse reactions to other HA products, or physician rationale for choosing high-molecular-weight HA
- Provider letter of medical necessity: This should address each denial reason directly
Step 3: Write Your Appeal Letter
If the denial is product-specific, emphasize why Orthovisc is the right product for you. If it is a medical necessity denial, focus on comprehensive documentation of your OA severity and treatment history. See the template below.
Step 4: Submit and Follow Up
Submit via your plan’s preferred channel. Keep copies. Confirm receipt within 5 business days. Request peer-to-peer review if available — this is especially useful for product-preference denials where your physician can explain the clinical reasoning directly.
Step 5: External Review Options
If internal appeal fails:
- Commercial plans: Independent external review through state insurance department
- Medicare Advantage: IRE, then ALJ if needed
- Original Medicare: Redetermination, then QIC reconsideration
Sample Appeal Letter Template
[Your Name] [Your Address] [City, State, ZIP] [Date]
[Insurance Company Name] [Appeals Department Address] [City, State, ZIP]
RE: Appeal of Denial — Orthovisc (hyaluronan) Injection Series Member ID: [Your Member ID] Claim Number: [Claim Number from Denial Letter] Date of Service: [Dates of Injections] Patient: [Your Name, DOB]
Dear Appeals Committee:
I am writing to appeal the denial of coverage for my Orthovisc injection series for [left/right] knee osteoarthritis, denied on [denial date] for the stated reason: “[exact denial reason].”
Diagnosis: Osteoarthritis of the [left/right] knee (ICD-10: [M17.11 or M17.12]), confirmed by X-rays on [date] showing [specific findings].
Why Orthovisc Specifically: [Choose the applicable reason:]
- I previously received Orthovisc on [date] with [X months] of meaningful pain relief and improved function. Retreatment with the same product that was previously effective is clinically appropriate.
- I experienced [adverse reaction] with [other HA product name] on [date], making Orthovisc the most appropriate alternative.
- My physician specifically recommends Orthovisc based on its high molecular weight and purity profile, which is clinically relevant to my condition severity.
Conservative Treatment History:
- Physical therapy: [number] sessions from [start date] to [end date]. Result: [limited relief].
- NSAIDs: [medication] [dosage] from [start date] to [end date]. Result: [insufficient pain control / GI side effects].
- Cortisone injection: [date]. Provided [X weeks] of relief.
- Activity modification: [specific changes made].
Functional Impact: My knee pain limits my ability to [specific activities affected].
I request reversal of this denial and authorization for Orthovisc. Supporting documentation is enclosed.
Sincerely, [Your Signature] [Your Printed Name] [Phone Number]
Enclosures: Denial letter, medical records, imaging reports, physician letter of medical necessity, conservative treatment records, prior Orthovisc treatment records (if applicable)
CPT and HCPCS Codes for Orthovisc
| Code Type | Code | Description |
|---|---|---|
| HCPCS (Product) | J7324 | Orthovisc, for intra-articular injection, per dose |
| CPT (Injection) | 20610 | Arthrocentesis, aspiration and/or injection of major joint (without ultrasound) |
| CPT (Injection w/ imaging) | 20611 | Arthrocentesis with ultrasound guidance |
| ICD-10 (Diagnosis) | M17.0 | Bilateral primary osteoarthritis of knee |
| ICD-10 (Diagnosis) | M17.11 | Primary osteoarthritis, right knee |
| ICD-10 (Diagnosis) | M17.12 | Primary osteoarthritis, left knee |
| Office Visit | 99213/99214 | Established patient office visit (if billed same day) |
Coding Note for Orthovisc
Orthovisc has its own dedicated J-code (J7324). Each injection in the 3-4 injection series is billed separately. The standard dose is 2 mL (30 mg hyaluronan) per injection. Make sure J7324 appears on every claim in the series — a generic HA code will cause a denial.
Orthovisc-Specific Coverage Facts
About Orthovisc
- Manufacturer: Anika Therapeutics (distributed by DePuy Synthes / Johnson & Johnson)
- Active ingredient: Ultra-pure, high molecular weight hyaluronan
- Molecular weight: High (1.0-2.9 million Daltons)
- Injection schedule: 3-4 weekly injections (2 mL each)
- FDA approved: Yes, for knee osteoarthritis
- Source: Avian-derived (rooster comb), highly purified
- Distinguishing feature: Among the highest purity profiles of avian-sourced HA products
Medicare Coverage
Original Medicare Part B covers Orthovisc for knee OA. Patients pay 20% coinsurance after the $257 deductible (2026). PA is generally not required under Original Medicare. Medicare Advantage plans may require PA and may steer toward preferred alternatives.
Commercial Insurance Coverage
Coverage varies significantly:
- Some plans list Orthovisc as a preferred product; others do not
- Prior authorization is almost always required
- Step therapy requirements (conservative treatment, sometimes cortisone first)
- Product-preference denials are more common with Orthovisc than with lower-cost products
- Formulary exceptions are available when you can demonstrate why Orthovisc is specifically needed
Common LCD Requirements
- Radiographic confirmation of knee osteoarthritis
- Failure of conservative therapy for 3+ months
- Minimum 6-month interval between injection series
- Coverage limited to knee joint
- Provider enrolled in Medicare (for Medicare claims)
Tips to Prevent Future Denials
- Check your plan’s preferred product list before starting treatment. If Orthovisc is not preferred, discuss with your provider whether it is clinically necessary or whether an alternative would be appropriate.
- Get prior authorization that specifically names Orthovisc (not just “viscosupplementation”)
- Document why Orthovisc is the right product — prior success, adverse reaction to alternatives, or physician clinical rationale
- Complete the full 3-4 injection series on the weekly schedule
- Use J7324 on all claims — verify with your provider’s billing office
- Keep detailed conservative treatment records with dates, durations, and specific outcomes
- Note avian allergy status in your chart since Orthovisc is avian-derived
Frequently Asked Questions
How long does an Orthovisc appeal take?
Internal appeals typically take 30 days. Expedited appeals take 72 hours. External reviews add 30-60 days. Full process: 4-12 weeks.
What is the success rate for Orthovisc appeals?
Product-preference denials (where the insurer wants you to use a different brand) can be harder to overturn unless you have a compelling reason for Orthovisc specifically. Medical necessity denials with complete documentation have a 40-60% overturn rate.
Can my doctor help with the appeal?
Your doctor’s letter is critical, especially for product-specific denials. Have your physician explain the clinical reasoning for choosing Orthovisc over alternatives. Peer-to-peer review with the plan’s medical director is particularly valuable for these cases.
What if my second appeal is denied?
Request an external review. If the denial was product-specific, consider whether switching to your plan’s preferred HA product is acceptable. If you have a medical reason for needing Orthovisc specifically, the external reviewer may overturn the denial.
My plan wants me to use a different brand. Should I switch?
Discuss this with your physician. If your plan prefers Hyalgan or Supartz and there is no clinical reason you need Orthovisc specifically, switching may be the fastest path to treatment. However, if you had prior success with Orthovisc or have a medical reason to use it, pursue the appeal.